Breaking News on Global Pharmaceutical Technology & Manufacturing

Ingredients: Top Headlines

Cambrex predicts flat generic API sales for 2016

Cambrex to start work on Pharma 4 API site in 2016


28-Jul-2016 - Cambrex has said it will invest around $20m in its Pharma 4 API facility before the end of the year in an effort to get ahead of the capacity utilisation curve.

Related news

News in brief

Dr Reddy’s Q1: warning letter ‘significantly impacted our earnings’

28-Jul-2016 - US FDA warnings and Venezuela's economic crisis have contributed to “a challenging quarter” for Dr Reddy’s, with its API business being particularly affected.

BASF reports lower demand for remaining APIs in Q2

27-Jul-2016 - BASF has said it saw lower demand for its remaining APIs in the second quarter.

Teewinot gets US patent for bioreactor used to make synthetic cannabinoid APIs

22-Jul-2016 - Teewinot Life Sciences has been granted a US patent for a bioreactor it uses to produce synthetic cannabinoids.


US investor buys J&J's opiate API business and announces restructuring

21-Jul-2016 - SK Capital has rejigged the senior teams at opiate API maker Noramco and raw material supplier Tasmanian Alkaloids just weeks after buying the firms from Johnson & Johnson (J&J).

Patheon will list on NYSE today

21-Jul-2016 - API and drug maker Patheon will begin trading on the New York Stock Exchange under the symbol PTHN later today.

Lonza: Biologic APIs boosted H1 revs and CAR-T deal will help sustain growth in H2

20-Jul-2016 - Lonza has increased its 2016 earnings guidance after strong H1 growth of its biologic APIs business.

Johnson Matthey: Q1 API revenues down on order timings

20-Jul-2016 - Johnson Matthey said a slight decrease in API sales during the first quarter of its fiscal year was due to the timing of customer orders.

Ingredients: Featured news

Key Industry Events


Access all events listing

Our events, Shows & Conferences...